Muco-Adhesive Levodopa Formulation for Steady Intestinal Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral levodopa formulations for Parkinson's disease suffer from 'peak-to-trough' fluctuations and inadequate duration-of-effect, necessitating a formulation that provides steadier plasma concentrations and longer therapeutic coverage.
Innovation Solution
A controlled release oral dosage form comprising levodopa with a muco-adhesive polymer and enteric coating, combined with a rate-controlling polymer, to delay stomach release and facilitate absorption in the small intestine, incorporating an immediate release component for rapid onset.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral levodopa is administered to treat Parkinson's disease, then therapeutic effect is achieved, but plasma concentration fluctuations and short duration of effect occur
Solution Approach 1:
The levodopa formulation is divided into multiple particles with different coating configurations. Some particles are enteric-coated to resist stomach acid and release in the intestine, while others are muco-adhesive to prolong residence time at the absorption site. This segmentation allows different portions of the dose to be released at different rates and locations, achieving both extended duration and stable plasma concentrations.
Solution Approach 2:
The levodopa particles are pre-coated with enteric and muco-adhesive polymers before administration. The enteric coating is designed to dissolve at specific pH levels in the intestine, and the muco-adhesive coating is pre-applied to enable immediate adhesion upon contact with intestinal mucosa. This preliminary preparation ensures controlled release kinetics and prolonged absorption without requiring complex post-administration mechanisms.
2Reliability
If intestinal infusion of levodopa is used to provide steady plasma levels, then motor fluctuations are reduced, but the delivery method becomes invasive and cumbersome
Solution Approach 1:
The muco-adhesive polymer acts as an intermediary between the levodopa particles and the intestinal mucosa. This polymer layer enables the particles to adhere to the intestinal wall, prolonging their residence time at the absorption site and mimicking the effect of continuous infusion without requiring invasive catheters or pumps. The enteric coating serves as another intermediary that protects levodopa from stomach acid and controls the location of release.
3Ease of operation
If oral delivery of levodopa is used, then convenience is improved, but plasma concentration control becomes difficult
Solution Approach 1:
Different particles in the formulation have different local qualities - some are enteric-coated for intestinal release, others are muco-adhesive for prolonged residence, and some combine both properties. This variation in local particle characteristics allows the formulation to achieve complex release patterns through simple oral administration, providing good plasma concentration control without requiring complex dosing regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves prolonged and steady therapeutic levodopa plasma levels, reducing motor fluctuations in Parkinson's disease patients by maintaining plasma concentrations above 50% of the maximum for at least 5.5 hours with minimal fluctuations.
Implementation Method 1
coated with a muco-adhesive polymer
Implementation Method 2
externally coated with an enteric coating polymer
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a controlled release oral solid formulation comparing (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.